Intelligence · Clinical Development
Pipeline search results
Programs matching “healthy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 1,124 pipeline programs matching "healthy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
Cohort 1: Lubiprostone Capsule, Fasted
Takeda
Healthy Volunteers
1 trial -
DR-1021
Teva Pharma GmbH
Healthy
1 trial -
MEQ00089
Sanofi Pasteur
Healthy volunteers (Meningococcal infection)
1 trial -
Placebo
Takeda
Healthy Volunteers
2 trials -
REGN10933 + REGN10987
Regeneron UK Limited
Healthy Participants
1 trial -
Rabies vaccine
Sinovac Research and Development Co.,
Rabies (Healthy Volunteers)
1 trial -
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]
Teva Pharma GmbH
Healthy
1 trial -
Sinovac rabies vaccine
Sinovac Research and Development Co.,
Rabies (Healthy Volunteers)
2 trials -
TAK-816
Takeda
Healthy Volunteers
1 trial -
TDV
Takeda
Healthy Volunteers
4 trials -
Tbo-filgrastim
Teva Pharma GmbH
Healthy Participants
1 trial -
V181
Merck KGaA, Darmstadt, Germany
Healthy
1 trial -
Vonoprazan
Takeda
Healthy Volunteers
1 trial -
ALN-4324
Alnylam Netherlands B.V.
Obese or Overweight Healthy Volunteers
1 trial -
ALN-PNP
Regeneron UK Limited
Healthy Volunteers
1 trial -
APHP221107
Pari Pharma GmbH
Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission
1 trial -
Atomoxetin STADA 40 mg Hartkapseln, GELATIN
Pari Pharma GmbH
Healthy subjects with no neurological or psychiatric disorders
1 trial -
BEX17850
Sanofi-aventis Healthcare Pty Ltd
Healthy volunteers
1 trial -
CLTP001A12202
Novartis Pharmaceuticals
Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
1 trial -
DR230330 – ANRS0514s
Tour Hekla
Healthy volunteers
1 trial -
Fentanyl
United Therapeutics Europe Ltd
Healthy
1 trial -
G03-52-01
United Therapeutics Europe Ltd
Healthy
1 trial -
GLS-5300
INOVIO PHARMACEUTICALS, INC.
Healthy
2 trials
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.